Group 1: Oil and Gas Sector - Oil stocks experienced a decline, with Sinopec (00386) down 3.89%, PetroChina (00857) down 3.17%, and CNOOC (00883) down 2.79%. This follows a drop in WTI crude oil futures by 2.77% to $62.84 per barrel and Brent crude by 2.71% to $67.52 per barrel [1] Group 2: Renewable Energy Sector - Solar stocks fell collectively, with Xinyi Solar (00968) down 3.62% and New Special Energy (01799) down 3.61%. The rise in silver prices has increased silver paste costs, impacting the battery and component sectors [1] Group 3: Precious Metals Sector - Lao Poo Gold (06181) saw a nearly 5% drop. Bank of America Securities reported that the company is expected to benefit from rising gold prices, with a projected revenue increase of 165% year-on-year for the second half of last year [1] Group 4: Pharmaceuticals - Zai Lab (09688) rose by 7% after its injection drug ZL-1310 was proposed for breakthrough therapy designation for extensive-stage small cell lung cancer (ES-SCLC), showing promising early clinical data [2] Group 5: Precision Manufacturing - China High Precision (00591) fell over 18% after issuing a profit warning, expecting a profit of approximately RMB 2.5 million to RMB 4.5 million for the six months ending December 31, 2025, due to project delays in the oil and petrochemical sectors [2] Group 6: Non-Ferrous Metals - Non-ferrous stocks faced significant declines, with China Nonferrous Mining (01258) down 5.08% and Zijin Mining (02899) down 5.29%. This is attributed to a "de-risking" sentiment in global financial markets, leading to a sell-off in precious metals [3] Group 7: Biotechnology - Xiansheng Pharmaceutical (02096) increased over 4.4% after announcing a licensing agreement with AbbVie for the investigational drug SIM0500, which includes upfront payments and potential milestone payments totaling up to $1.055 billion [3] Group 8: Gaming Sector - Gaming stocks declined, with Melco International Development (00200) down 6.21%. Wynn Macau reported a 7% year-on-year drop in EBITDA for Q4 2025, which was below market expectations [4] Group 9: Oilfield Services - Anton Oilfield Services (03337) rose over 9% after announcing a profit forecast of approximately RMB 360 million to RMB 380 million for 2025, representing a significant year-on-year increase of 48.4% to 56.6% [4] Group 10: U.S. Market Movements - Arko Petroleum (APC.US) opened with a 2.5% decline after its market debut. The company delivered 1.5 billion gallons of fuel in the nine months ending September 30, 2025 [5] - Albemarle (ALB.US) fell 9.41% despite a 16% year-on-year increase in Q4 sales to $1.4 billion, reporting a net loss of $414 million [5] - Boeing (BA.US) rose 1.31% as it plans to increase the monthly production of its 737 series aircraft to 63 units in the coming years [5] Group 11: Technology Sector - Cisco (CSCO.US) dropped 12.32% as it projected a decline in adjusted gross margin for Q3, indicating a worsening trend compared to previous quarters [7] - Storage stocks saw gains, with SanDisk (SNDK.US) up 5.16% and Western Digital (WDC.US) up 3.78% [7]

Group 1 - The core point of the article is that Yiming Pharmaceutical (002826) has announced a draft for a restricted stock incentive plan for 2026, aimed at establishing an employee incentive mechanism, which may positively impact the company's long-term development [1][2]. Group 2 - On February 10, 2026, the company's board approved the draft of the restricted stock incentive plan, indicating a strategic move to enhance employee motivation and retention [2]. - The company's stock price experienced significant fluctuations over the past seven trading days, with a cumulative decline of approximately 4.38% from February 9 to 11, followed by a rebound of 2.51% on February 12, closing at 20.79 yuan [3]. - On February 12, there was a net inflow of approximately 6.6451 million yuan in main funds, accounting for 3.33% of the total trading volume, suggesting signs of short-term capital involvement [3]. - The company's stock performance was weaker compared to the pharmaceutical and biological sector and the overall market index during the same period [3].

Core Viewpoint - Multiple Wall Street institutions have updated their ratings and target prices for QGEN.N, reflecting a positive outlook on the company's performance and growth potential [1][2] Group 1: Ratings and Target Prices - Morgan Stanley maintains a "Buy" rating with a target price of $60 [1] - Citigroup holds a "Hold" rating, raising its target price from $52.86 to $55 [1] - Barclays maintains a "Buy" rating, increasing its target price from $55 to $58 [1] - Baird downgraded its rating to "Hold," but raised its target price from $48.42 to $53 [1] Group 2: Financial Performance Expectations - The forecast for Q1 2026 includes revenue of approximately $504 million, representing a year-over-year growth of 7.57% [1] - Expected net profit for the same period is around $114 million, showing a year-over-year increase of 3.07% [1] - The company's financial performance is a key factor influencing stock price movements [1] Group 3: Stock Performance - Over the recent week (February 6 to February 12, 2026), QGEN.N's stock price fluctuated between $50.53 and $51.71, with a volatility of 2.32% and a trading volume of approximately $361 million [1] - As of February 12, the stock closed at $51.13, with a slight increase of 0.14%, while the Nasdaq index fell by 1.55% and the life sciences sector declined by 2.59%, indicating relative stability in the company's performance [1] Group 4: Recent Events - On February 6, 2026, several institutions updated their ratings, with target prices moving to a range of $53 to $60, reflecting market divergence and focus on growth [2] - The company's fiscal year 2025 report indicated a revenue increase of 5.65% and a net profit surge of 408.28%, although there have been no significant company announcements recently [2]

Core Viewpoint - The article discusses the efforts of the Min County Market Supervision Administration to regulate market prices during the holiday season, ensuring consumer rights and preventing price gouging and fraud [1][3]. Group 1: Regulatory Actions - The Min County Market Supervision Administration organized inspections of major supermarkets, wholesale markets, and pharmacies to monitor prices of essential goods such as rice, flour, oil, meat, eggs, milk, and medicines [1]. - Inspections focused on promotional pricing, price fluctuations of essential goods, and compliance with clear pricing regulations, targeting issues like false promotions and rapid price increases [3]. Group 2: Enforcement and Compliance - A total of 52 enforcement personnel were deployed, inspecting one grain and oil reserve point, five supermarkets, one wholesale market, and three pharmacies, resulting in the identification of one entity with non-compliant pricing and another with improper promotional signage, both of which were ordered to rectify immediately [5]. - The market price operation during the holiday period has remained stable [5]. Group 3: Future Plans - The Min County Market Supervision Administration plans to increase the frequency of market inspections and enforcement efforts, while also improving consumer complaint channels to strengthen market price stability during the holiday season [6].

Core Viewpoint - The issuance of the "Several Measures to Support the High-Quality Development of Commercial Health Insurance in Beijing" aims to promote the high-quality development of commercial health insurance and improve the multi-level medical security system in the capital [2]. Group 1: Measures for Development - The measures include six aspects focusing on enhancing insurance product innovation, encouraging the development of diverse insurance products that meet citizens' needs [1]. - There is an emphasis on deepening collaboration between commercial insurance and the pharmaceutical industry, promoting communication and cooperation to include innovative drugs and medical devices in insurance coverage [1]. - The initiative aims to improve service capabilities by increasing support for purchasing commercial insurance products and optimizing service experiences [1]. Group 2: Operational Enhancements - The measures promote a "one-stop" settlement model for medical insurance and commercial insurance, aiming to enhance service efficiency and reduce patient burden [1]. - Strengthening consumer rights protection and regulatory compliance is a key focus, with an aim to improve regulatory capabilities and market order [1]. - Establishing a cross-departmental collaborative work mechanism is intended to facilitate the orderly connection of multi-level medical security [1].

泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能力。由于短期利好 因素已反映在股价，相信其风险与回报已趋于平衡。 里昂发布研报称，下调泰格医药（300347）(03347)2027财年盈测7%，以反映长期投资收益的不确定因 素增加。该行续予泰格医药"跑赢大市"评级，当中将H股目标价由68.2港元下调至59.9港元，并将泰格 医药(300347.SZ)A股目标价由81.9元人民币降至72元人民币。 ...

Investment Rating - The report assigns an "Accumulate" rating to Kelun Pharmaceutical [13] Core Views - The approval of the fourth indication for the subsidiary's core asset SKB264 in China is a positive development, indicating that the sales of innovative drugs are gradually materializing, and there is an expectation for the recovery of the main business [2][13] - The report anticipates total revenue for 2025-2027 to be 174.2 billion, 197.6 billion, and 225.7 billion yuan, respectively, with year-on-year growth rates of -20.1%, 13.4%, and 14.2% [13] - Expected EPS for 2025-2027 is projected to be 0.93, 1.14, and 1.72 yuan [13] - The report highlights that Kelun Pharmaceutical, as a leading company in the industry, has stable business development, and the first product from Kelun Botai is about to be launched overseas, which supports the outlook for the company's innovative drug business [13] Financial Summary - Total revenue for 2023 is projected at 21,454 million yuan, with a year-on-year increase of 12.7% [5] - Net profit attributable to the parent company is expected to be 2,456 million yuan in 2023, reflecting a significant increase of 44.0% [5] - The report provides a detailed financial forecast, including revenue and net profit projections for the next five years, indicating fluctuations in growth rates [5][16] Market Data - The stock price range over the past 52 weeks is between 26.85 and 40.70 yuan, with a total market capitalization of 51,218 million yuan [8] - The report notes that the company has a total equity of 23,708 million yuan and a net asset per share of 14.84 yuan [9] Clinical Development - Kelun Botai has initiated nine registration clinical studies for SKB264 in China, with significant clinical trial results indicating improved progression-free survival (PFS) and overall survival (OS) rates compared to chemotherapy [13]

Investment Rating - The report assigns an "Accumulate" rating to Kelun Pharmaceutical [13] Core Views - The core asset SKB264 of the subsidiary has received approval for its fourth indication in China, indicating a positive outlook for the sales of innovative drugs and an expectation for the recovery of the main business [2][13] - The report anticipates total revenue for 2025-2027 to be 174.2 billion, 197.6 billion, and 225.7 billion yuan, respectively, with year-on-year growth rates of -20.1%, 13.4%, and 14.2% [13] - Expected EPS for 2025-2027 is projected to be 0.93, 1.14, and 1.72 yuan [13] - The report highlights the stable development of various business segments and the upcoming overseas launch of the first product from Kelun Botai, supporting the continued realization of the company's innovative drug business [13] Financial Summary - Total revenue for 2023 is projected at 21,454 million yuan, with a year-on-year growth of 12.7% [5] - Net profit attributable to the parent company is expected to be 2,456 million yuan in 2023, reflecting a significant increase of 44.0% [5] - The report forecasts a net profit margin of 12.3% for 2023, with a projected increase to 14.0% by 2027 [16] - The company’s total assets are estimated to reach 42,588 million yuan by 2027, with a debt-to-equity ratio of 22.9% [16] Market Data - The stock price range over the past 52 weeks is between 26.85 and 40.70 yuan, with a total market capitalization of 51,218 million yuan [8] - The report sets a target price of 45.41 yuan based on a 40x PE ratio for 2026 [13]

Economic Indicators - The manufacturing PMI for January 2026 is 49.3%, a decrease of 0.8 percentage points from the previous month, indicating a slowdown in manufacturing activity[4] - The CPI growth rate for January 2026 is 0.2%, primarily due to the high base effect from the previous year's Spring Festival[6] - The PPI for January 2026 is -1.4%, with a narrowing decline of 0.5 percentage points, reflecting improved internal structure and demand driven by technology[6] Trade and Investment - In December 2025, China's total imports and exports amounted to $601.42 billion, with exports increasing by 6.6% and imports rising by 5.7% year-on-year[20] - The M1 growth rate in December 2025 fell to 3.8%, while M2 grew by 8.5%, leading to an expanding M1-M2 gap of -4.7%[34] - The real estate market shows signs of recovery, with new home prices averaging 17,114 RMB per square meter, a month-on-month increase of 0.18%[48] Sector Performance - The service sector's business activity index has stabilized around 49.5% for three consecutive months, supported by financial activities and holiday-related consumption[4] - The consumer goods sector experienced a decline of 2.2 percentage points, primarily due to a drop in clothing orders[27] - The equipment sector shows resilience, with significant demand for computers and automation equipment, indicating a positive trend in industrial investment[28]

2026.02. 12 本文字数：26863，阅读时长大约5分钟 作者 | 第一 财经 吴斯旻 2月11日，国家卫生健康委等11部门联合印发新版《国家基本药物目录管理办法》（下称"管理办 法"），并于发布之日起施行。原国家卫计委2015年2月13日发布的旧版基药目录管理办法同时废 除。 国家基本药物制度是国家药品供应保障体系的基础，各级医疗卫生机构需形成以基本药物为主导 的"1+X"用药模式。自2009年新一轮医改启动中国基本药物制度建设以来，基药目录清单经历了 2012年、2018年两次更新调整。 近年来，国内外创新机制治疗药品快速进入临床使用，临床用药结构发生了显著变化。与此同时，由 于基本药物制度并无筹资体系和支付机制，临床使用时还是需要靠品种纳入医保目录后用医保基金支 付。所以基药目录的更新频次、结构优化方向备受关注。 作为基药制度的重要配套文件，新修订版管理办法提出基药目录遴选应"突出药品临床价值"，强 调"调整周期原则上不超过3年"的制度刚性，同时明确基药目录与医保目录，以及与集采、分级诊疗 等政策的衔接和协同。 突出药品临床价值 基本药物是指满足疾病防治基本用药需求，适应现阶段基本国情和保障能力 ...